Trial Profile

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 07 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Colon cancer
Focus Biomarker; Pharmacodynamics; Therapeutic Use
Acronyms COBRA

Most Recent Events

27 Apr 2025 Planned End Date changed from 30 Apr 2027 to 21 Jun 2026.
12 Feb 2024 Status changed from recruiting to active, no longer recruiting.
20 Jan 2024 According to Results presented at the 2024 Gastrointestinal Cancers Symposium, further enrollment has been halted based upon pre-specified study stopping rules utilizing the original assay.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com